Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jacob George

Showing results (741-750 of 849) with videos related to

Pageof 85
Sort By:
Journal of Hepatology|November 4, 2018
A polymorphism in the Irisin-encoding gene (FNDC5) associates with hepatic steatosis by differential miRNA binding to the 3'UTRMayada Metwally, Ali Bayoumi, Manuel Romero-Gomez, et al.
Scientific Reports|October 18, 2019
IFNL3 genotype is associated with pulmonary fibrosis in patients with systemic sclerosisMayada Metwally, Khaled Thabet, Ali Bayoumi, et al.
Egastroenterology|December 29, 2025
Metabolic dysfunction and alcohol-associated liver disease (MetALD)Bin Gao, Juan Pablo Arab, Suthat Liangpunsakul, et al.
The Medical Journal of Australia|July 28, 2025
Assessment of metabolic dysfunction-associated fatty liver disease in primary care: a consensus statement summaryLeon A Adams, William W Kemp, Kate R Muller, et al.
Drug and Alcohol Dependence|August 3, 2007
Modelling the hepatitis C virus epidemic in AustraliaKarina Razali, Hla Hla Thein, Jane Bell, et al.
ESC Heart Failure|May 17, 2021
Neutrophil-to-lymphocyte ratio and outcomes in patients with new-onset or worsening heart failure with reduced and preserved ejection fractionFraser M Curran, U Bhalraam, Mohapradeep Mohan, et al.
Alimentary Pharmacology & Therapeutics|January 6, 2022
Liver-related and extrahepatic events in patients with non-alcoholic fatty liver disease: a retrospective competing risks analysisGrazia Pennisi, Marco Enea, Manuel Romero-Gomez, et al.
Hepatology (Baltimore, Md.)|October 5, 2023
Risk of liver-related events in metabolic dysfunction-associated steatohepatitis (MASH) patients with fibrosis: A comparative analysis of various risk stratification criteriaGrazia Pennisi, Marco Enea, Manuel Romero-Gomez, et al.
Hepatology (Baltimore, Md.)|July 18, 2018
ADAPT: An Algorithm Incorporating PRO-C3 Accurately Identifies Patients With NAFLD and Advanced FibrosisSamuel J Daniels, Diana J Leeming, Mohammed Eslam, et al.
Journal of Gastroenterology and Hepatology|February 16, 2026
A Novel Fibroblast Activation Protein-Based Algorithm to Assess Fibrosis in Metabolic Dysfunction-Associated Steatotic Liver DiseaseZiqi V Wang, Badwi B Boumelhem, Torsten Pennell, et al.
Pageof 85

Showing results (741-750 of 849) with videos related to

Sort By:
Pageof 85
Journal of Hepatology|November 4, 2018
A polymorphism in the Irisin-encoding gene (FNDC5) associates with hepatic steatosis by differential miRNA binding to the 3'UTRMayada Metwally, Ali Bayoumi, Manuel Romero-Gomez, et al.
Scientific Reports|October 18, 2019
IFNL3 genotype is associated with pulmonary fibrosis in patients with systemic sclerosisMayada Metwally, Khaled Thabet, Ali Bayoumi, et al.
Egastroenterology|December 29, 2025
Metabolic dysfunction and alcohol-associated liver disease (MetALD)Bin Gao, Juan Pablo Arab, Suthat Liangpunsakul, et al.
The Medical Journal of Australia|July 28, 2025
Assessment of metabolic dysfunction-associated fatty liver disease in primary care: a consensus statement summaryLeon A Adams, William W Kemp, Kate R Muller, et al.
Drug and Alcohol Dependence|August 3, 2007
Modelling the hepatitis C virus epidemic in AustraliaKarina Razali, Hla Hla Thein, Jane Bell, et al.
ESC Heart Failure|May 17, 2021
Neutrophil-to-lymphocyte ratio and outcomes in patients with new-onset or worsening heart failure with reduced and preserved ejection fractionFraser M Curran, U Bhalraam, Mohapradeep Mohan, et al.
Alimentary Pharmacology & Therapeutics|January 6, 2022
Liver-related and extrahepatic events in patients with non-alcoholic fatty liver disease: a retrospective competing risks analysisGrazia Pennisi, Marco Enea, Manuel Romero-Gomez, et al.
Hepatology (Baltimore, Md.)|October 5, 2023
Risk of liver-related events in metabolic dysfunction-associated steatohepatitis (MASH) patients with fibrosis: A comparative analysis of various risk stratification criteriaGrazia Pennisi, Marco Enea, Manuel Romero-Gomez, et al.
Hepatology (Baltimore, Md.)|July 18, 2018
ADAPT: An Algorithm Incorporating PRO-C3 Accurately Identifies Patients With NAFLD and Advanced FibrosisSamuel J Daniels, Diana J Leeming, Mohammed Eslam, et al.
Journal of Gastroenterology and Hepatology|February 16, 2026
A Novel Fibroblast Activation Protein-Based Algorithm to Assess Fibrosis in Metabolic Dysfunction-Associated Steatotic Liver DiseaseZiqi V Wang, Badwi B Boumelhem, Torsten Pennell, et al.
Pageof 85